Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Alexion now officially part of AstraZeneca

New Haven-born Alexion Pharmaceuticals, whose blockbuster blood-disorder drug Soliris made it one of the Elm City’s biggest biotech success stories a decade ago, is now...

| By Kelley Gipson

InveniAI in collaboration with PRISM BioLab

InveniAI® has completed a milestone in its collaboration with PRISM BioLab. The milestone marks completion of the identification and validation of a small molecule drug candidate...

| By Kelley Gipson

Yale seen as growth engine for New Haven

Lauren Zucker is Yale University’s associate vice president for New Haven Affairs and University Properties. New Haven BIZ recently spoke with Zucker about Yale’s efforts to drive...

| By Kelley Gipson

Stamford’s Sema4 going public

Stamford health intelligence company Sema4 has completed its business combination with CM Life Sciences, paving the way for the combined company – Sema4 Holdings Corp....

| By Kelley Gipson

Biorez wins major award for BioBrace Implant

Biorez reports that its proprietary, and recently FDA-cleared BioBrace Implant, received the AOSSM ACE Award for ‘Accelerating the Cutting Edge.’ The award was given at...

| By Kelley Gipson

Venture capital funding driving demand for CFOs

In Connecticut, startups — predominantly technology or life sciences ventures located in Greater New Haven — hauled in more than $707 million in funding in...

| By Kelley Gipson

Thetis adds to cancer program and SAB

Thetis Pharmaceuticals reports the launch of a new program in cancer. Thetis CEO Gary Mathias said, “We are targeting pancreatic, metastatic colorectal, small cell lung...

| By Kelley Gipson

UConn studying jaw pain, solid tumors

Pain where the jaw hinges to the skull is both common and difficult to treat. Killing off aged cells might be the secret to healing...